Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations Meeting Abstract
| Authors: | Harding, J.; Perez, C.; Kato, S.; Sharma, M.; Garmezy, B.; Quah, C.; Tam, B.; Severson, P. |
| Abstract Title: | Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations |
| Meeting Title: | 25th World Congress on Gastrointestinal Cancer (ESMO 2023) |
| Keywords: | oncology |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Jun 28-Jul 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-06-01 |
| Start Page: | S63 |
| End Page: | S64 |
| Language: | English |
| ACCESSION: | WOS:001037960400138 |
| DOI: | 10.1016/j.annonc.2023.04.193 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: P-137 -- Source: Wos |
